drugset / Trial / NCT02546284
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, repeat-dose, Phase 1 Dose Escalation Study to evaluate safety, pharmacokinetics, and clinical activity.
Timeline
- Start
- 2016-07
- Primary completion
- 2020-02
- Completion
- 2020-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenzilumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Lenzilumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | Lenzilumab | Monoclonal antibody | 600 mg | Intravenous |